vs
VICOR CORP（VICR）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是VICOR CORP的1.1倍（$127.1M vs $113.0M），VICOR CORP同比增速更快（20.2% vs 17.1%），过去两年再鼎医药的营收复合增速更高（20.8% vs 14.7%）
Vicor Corporation是总部位于美国马萨诸塞州安多弗的电源模块专业制造商，深耕高性能电源模块的研发、生产与销售，可为多个行业客户提供高效可靠的电源解决方案，在全球电源技术领域具备较强的技术优势与市场竞争力。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
VICR vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.1倍
$113.0M
营收增速更快
VICR
高出3.1%
17.1%
两年增速更快
ZLAB
近两年复合增速
14.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $113.0M | $127.1M |
| 净利润 | $20.7M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 59.7% | -54.6% |
| 净利率 | 18.3% | — |
| 营收同比 | 20.2% | 17.1% |
| 净利润同比 | 713.9% | — |
| 每股收益（稀释后） | $0.44 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收VICRZLAB
| Q1 26 | $113.0M | — | ||
| Q4 25 | $107.3M | $127.1M | ||
| Q3 25 | $110.4M | $115.4M | ||
| Q2 25 | $96.0M | $109.1M | ||
| Q1 25 | $94.0M | $105.7M | ||
| Q4 24 | $96.2M | $108.5M | ||
| Q3 24 | $93.2M | $101.8M | ||
| Q2 24 | $85.9M | $100.1M |
净利润VICRZLAB
| Q1 26 | $20.7M | — | ||
| Q4 25 | $46.5M | — | ||
| Q3 25 | $28.3M | $-36.0M | ||
| Q2 25 | $41.2M | $-40.7M | ||
| Q1 25 | $2.5M | $-48.4M | ||
| Q4 24 | $10.2M | — | ||
| Q3 24 | $11.6M | $-41.7M | ||
| Q2 24 | $-1.2M | $-80.3M |
毛利率VICRZLAB
| Q1 26 | — | — | ||
| Q4 25 | 55.4% | 51.0% | ||
| Q3 25 | 57.5% | 59.5% | ||
| Q2 25 | 95.9% | 60.6% | ||
| Q1 25 | 47.2% | 63.6% | ||
| Q4 24 | 52.4% | 61.5% | ||
| Q3 24 | 49.1% | 64.1% | ||
| Q2 24 | 49.8% | 64.9% |
营业利润率VICRZLAB
| Q1 26 | 59.7% | — | ||
| Q4 25 | 14.6% | -54.6% | ||
| Q3 25 | 18.9% | -42.3% | ||
| Q2 25 | 47.3% | -50.3% | ||
| Q1 25 | -0.2% | -53.3% | ||
| Q4 24 | 9.6% | -62.6% | ||
| Q3 24 | 5.8% | -66.6% | ||
| Q2 24 | 0.2% | -76.0% |
净利率VICRZLAB
| Q1 26 | 18.3% | — | ||
| Q4 25 | 43.4% | — | ||
| Q3 25 | 25.6% | -31.2% | ||
| Q2 25 | 42.9% | -37.3% | ||
| Q1 25 | 2.7% | -45.8% | ||
| Q4 24 | 10.7% | — | ||
| Q3 24 | 12.4% | -40.9% | ||
| Q2 24 | -1.4% | -80.2% |
每股收益（稀释后）VICRZLAB
| Q1 26 | $0.44 | — | ||
| Q4 25 | $1.01 | $-0.05 | ||
| Q3 25 | $0.63 | $-0.03 | ||
| Q2 25 | $0.91 | $-0.04 | ||
| Q1 25 | $0.06 | $-0.04 | ||
| Q4 24 | $0.24 | $-0.09 | ||
| Q3 24 | $0.26 | $-0.04 | ||
| Q2 24 | $-0.03 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $404.2M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $754.1M | $715.5M |
| 总资产 | $804.9M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资VICRZLAB
| Q1 26 | $404.2M | — | ||
| Q4 25 | $402.8M | $689.6M | ||
| Q3 25 | $362.4M | $717.2M | ||
| Q2 25 | $338.5M | $732.2M | ||
| Q1 25 | $296.1M | $757.3M | ||
| Q4 24 | $277.3M | $779.7M | ||
| Q3 24 | $267.6M | $616.1M | ||
| Q2 24 | $251.9M | $630.0M |
股东权益VICRZLAB
| Q1 26 | $754.1M | — | ||
| Q4 25 | $711.6M | $715.5M | ||
| Q3 25 | $630.1M | $759.9M | ||
| Q2 25 | $608.6M | $791.7M | ||
| Q1 25 | $580.3M | $810.8M | ||
| Q4 24 | $570.1M | $840.9M | ||
| Q3 24 | $554.6M | $667.7M | ||
| Q2 24 | $537.2M | $704.2M |
总资产VICRZLAB
| Q1 26 | $804.9M | — | ||
| Q4 25 | $785.8M | $1.2B | ||
| Q3 25 | $710.2M | $1.2B | ||
| Q2 25 | $693.5M | $1.2B | ||
| Q1 25 | $665.0M | $1.2B | ||
| Q4 24 | $641.1M | $1.2B | ||
| Q3 24 | $632.8M | $985.3M | ||
| Q2 24 | $613.2M | $987.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流VICRZLAB
| Q1 26 | — | — | ||
| Q4 25 | $15.7M | $-26.0M | ||
| Q3 25 | $38.5M | $-32.0M | ||
| Q2 25 | $65.2M | $-31.0M | ||
| Q1 25 | $20.1M | $-61.7M | ||
| Q4 24 | $10.1M | $-55.8M | ||
| Q3 24 | $22.6M | $-26.8M | ||
| Q2 24 | $15.6M | $-42.2M |
自由现金流VICRZLAB
| Q1 26 | — | — | ||
| Q4 25 | $10.2M | $-26.7M | ||
| Q3 25 | $34.5M | $-35.0M | ||
| Q2 25 | $59.0M | $-33.9M | ||
| Q1 25 | $15.6M | $-63.2M | ||
| Q4 24 | $8.4M | $-58.4M | ||
| Q3 24 | $14.1M | $-28.2M | ||
| Q2 24 | $9.4M | $-42.9M |
自由现金流率VICRZLAB
| Q1 26 | — | — | ||
| Q4 25 | 9.5% | -21.0% | ||
| Q3 25 | 31.2% | -30.4% | ||
| Q2 25 | 61.5% | -31.1% | ||
| Q1 25 | 16.6% | -59.9% | ||
| Q4 24 | 8.7% | -53.8% | ||
| Q3 24 | 15.2% | -27.7% | ||
| Q2 24 | 11.0% | -42.9% |
资本支出强度VICRZLAB
| Q1 26 | — | — | ||
| Q4 25 | 5.2% | 0.5% | ||
| Q3 25 | 3.6% | 2.6% | ||
| Q2 25 | 6.5% | 2.6% | ||
| Q1 25 | 4.8% | 1.5% | ||
| Q4 24 | 1.8% | 2.4% | ||
| Q3 24 | 9.1% | 1.3% | ||
| Q2 24 | 7.2% | 0.7% |
现金转化率VICRZLAB
| Q1 26 | — | — | ||
| Q4 25 | 0.34× | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 1.58× | — | ||
| Q1 25 | 7.93× | — | ||
| Q4 24 | 0.99× | — | ||
| Q3 24 | 1.95× | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
VICR
| Product revenue | $98.0M | 87% |
| Royalty revenue | $15.0M | 13% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
